Back to search results

Phase 2 Study of DISC-3405 for Polycythemia Vera (PV)

This study is testing a new drug called DISC-3405 for people with Polycythemia Vera (PV), a blood disorder where your body makes too many red blood cells. DISC-3405 is given as a shot under the skin. Researchers want to see how safe DISC-3405 is, if it causes any side effects, and how well it works. To join, you must be 18 or older and meet specific blood count requirements, including having a hematocrit (HCT) below 45% (or 48% if you've had a recent blood draw). The study will look at side effects and changes in your vital signs and physical exam for up to 365 days. The current recruitment status is unclear.

Study design
This is an open-label study, meaning both you and the study team will know you are receiving DISC-3405. It will involve about 60 participants and will test up to two different dose levels of the drug.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your safety will be monitored for up to 365 days after starting the treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06985147

A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

Active, Not Recruiting
PHASE2Ages 18+InterventionalTreatment
Disc Medicine, Inc
~60 participants
Updated 2026-07-31 on ClinicalTrials.gov
What's tested:DISC-3405

At a glance

Recruiting sites
0 of 15 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants with treatment-related adverse events as assessed by CTCAE
Measured over Up to 365 days
+4 more outcomes measured

Conditions

Polycythemia Vera (PV)

Explore related trials

Polycythemia Vera

Where it's being run

15 sites across 10 states
California3
North Carolina3
Ohio2
Arizona1
Florida1
Minnesota1
Missouri1
Oregon1

Study leadership

  • Will Savage, MD PhD · STUDY_DIRECTOR · Disc Medicine

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Number of participants with treatment-related adverse events as assessed by CTCAEUp to 365 days

    Proportion of participants with treatment-emergent adverse events

  • Incidence of clinically abnormal vital signsUp to 365 days

    Proportion of participants with changes in vital signs

  • Incidence of clinically abnormal physical examUp to 365 days

    Proportion of participants with changes in physical examinations

  • Incidence of clinically abnormal electrocardiogramsUp to 365 days

    Proportion of participants with changes in electrocardiograms (ECGs)

  • Incidence of abnormal laboratory test resultsUp to 365 days

    Proportion of participants with changes in clinical laboratory results